Menu
Search Clinical Trials
Back to Search Results
Study Complete
Astellas Study ID
IDTX-MA-3004

To compare the effects of immediate-release tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) formation and the development of Immune Activation (IA) in de novo kidney transplant recipients

Astellas Study ID
IDTX-MA-3004
Clinicaltrials.gov ID
NCT02723591
EUCTIS ID
N/A
EudraCT ID
2018-003867-79
jRCT ID
N/A
CN CDE ID
N/A
Get more information

Study summary

This study compared the incidence of a two-part composite endpoint consisting of de novo donor specific antibody (DSA) formation or a designation of immune activation (IA) on peripheral blood molecular profiling in participants maintained on twice daily, immediate-release tacrolimus versus those maintained on Astagraf XL in the first year post-transplant.

Additional Study Details

Phase
4
Product
N/A
Product
Tacrolimus
Tacrolimus immediate release
Type
Interventional
Masking
None (Open Label)
Enrollment number
599
Show Additional Study Details

Study documents

Scientific Results Summary
Available Language(s): English
Download Document(s)
Plain Language Summary
Available Language(s): English
Download Document(s)
Protocol
Available Language(s): English
Download Document(s)
Statistical Analysis Plan (SAP)
Available Language(s): English
Download Document(s)

Get more information

Would you like more information about clinical trial sites that are recruiting participants for To compare the effects of immediate-release tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) formation and the development of Immune Activation (IA) in de novo kidney transplant recipients? Contact us by filling out your information to the right and we’ll respond to you.

  • A caregiver
  • A healthcare provider
  • A parent
  • A patient
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Completed
    Site US10023
    Madison, WI, United States, 53792
    Contact Us
    Completed
    Site US10037
    New York, NY, United States, 10032
    Contact Us
    Completed
    Site US10002
    Charleston, SC, United States, 29425
    Contact Us
    Completed
    Site US10020
    Chicago, IL, United States, 60605
    Contact Us
    Completed
    Site US10021
    Syracuse, NY, United States, 13210
    Contact Us
    Completed
    Site US10001
    Baltimore, MD, United States, 21201
    Contact Us
    Completed
    Site US10005
    Sacramento, CA, United States, 95817
    Contact Us
    Completed
    Site US10014
    Washington, DC, United States, 20007
    Contact Us
    Completed
    Site US10029
    Minneapolis, MN, United States, 55455
    Contact Us
    Completed
    Site US10027
    Rochester, MN, United States, 55905
    Contact Us
    Completed
    Site US10003
    New Haven, CT, United States, 06510
    Contact Us
    Completed
    Site US10028
    New York, NY, United States, 10467
    Contact Us
    Completed
    Site US10031
    Los Angeles, CA, United States, 90033
    Contact Us
    Completed
    Site US10016
    San Francisco, CA, United States, 94115
    Contact Us
    Completed
    Site US10013
    Ann Arbor, MI, United States, 48109
    Contact Us
    Completed
    Site US10022
    New York City, NY, United States, 10065
    Contact Us
    Completed
    Site US10036
    Houston, TX, United States, 77030
    Contact Us
    Completed
    Site US10019
    Livingston, NJ, United States, 07039
    Contact Us
    Completed
    Site US10018
    Salt Lake City, UT, United States, 84112
    Contact Us
    Completed
    Site US10012
    Charlottesville, VA, United States, 22903
    Contact Us
    Completed
    Site US10008
    Falls Church, VA, United States, 22042
    Contact Us
    Completed
    Site US10010
    Chicago, IL, United States, 60611
    Contact Us
    Completed
    Site US10007
    Boston, MA, United States, 02114
    Contact Us
    Completed
    Site US10026
    Portland, OR, United States, 97210
    Contact Us
    Completed
    Site US10032
    Detroit, MI, United States, 48202
    Contact Us
    Completed
    Site US10004
    Buffalo, NY, United States, 14215
    Contact Us
    Completed
    Site US10024
    Aurora, CO, United States, 80045
    Contact Us
    Completed
    Site US10006
    Birmingham, AL, United States, 35294
    Contact Us
    Withdrawn
    Site US10035
    Los Angeles, CA, United States, 90048
    Contact Us
    Completed
    Site US10025
    Scottsdale, AZ, United States, 85259
    Contact Us
    Completed
    Site US10030
    Jacksonville, FL, United States, 32224
    Contact Us
    Trial info
    Follow Trial
    Age
    16 - 70 years
    Diamond icon
    Condition
  • Kidney Transplants
    • Gender icon
    Sex
    Female & Male
    Calendar icon
    Trial Dates
    Sep 2016 - Jun 2019
    Additional Study Details
    Inclusion Criteria
    • Recipient of a de novo kidney from a living or deceased donor. Note: Recipient of an en bloc deceased donor kidney transplant from a pediatric donor ≥5 years of age AND weighing greater than 20 kg is allowed.
    • If deceased donor, a Kidney Donor Profile Index (KDPI) ≤ 85 (Donation after Circulatory Death [DCD] and what was previously known as extended criteria donor [ECD] organ recipients are eligible for enrollment provided KDPI ≤85).
    • At least one antigen mismatch at major Major Histocompatibility Complex (MHC) (class I or class II).
    • Willingness to comply with study protocol.
    • Subject agrees not to participate in another investigational drug study while on treatment.
    • Female subject must be either:

      • a. Of non-child-bearing potential

      i. Post-menopausal (defined as at least 1 year without any menses) prior to screening, or

      ii. Documented surgically sterile or status post-hysterectomy

      b. Or, if of childbearing potential,

      i. Agree not to try to become pregnant during the study and for 90 days after the final study drug administration

      ii. And have a negative serum or urine pregnancy test within 7 days prior to transplant procedure

      iii. And, if heterosexually active, agree to consistently use two forms of highly effective birth control (at least one of which must be a barrier method) which includes consistent and correct usage of established oral contraception, established intrauterine device or intrauterine system, or barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository or vasectomy in the male partner, starting at screening and throughout the study period and for 90 days after the final study drug administration.

    • Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at screening and continuing throughout the study period and for 90 days after the final study drug administration.
    • Male subject must not donate sperm starting at screening throughout the study period and for 90 days after the final study drug administration.
    • Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 90 days after the final study drug administration.
    • Female subject must not donate ova starting at screening and throughout the study period, and for 90 days after the final study drug administration.
    • Will be receiving induction immunotherapy (either T-cell depleting agent, anti-CD52 monoclonal antibody, or Interleukin-2 (IL-2) co-stimulation blocker), with dose and frequency of the chosen induction agent determined by local standard of care. Steroid-only induction therapy does not satisfy this criterion.
    MaximizeExclusion Criteria
    • Patient is known to have a positive test for latent Tuberculosis (TB) and has not previously received adequate anti-microbial therapy or would require TB prophylaxis after transplant.
    • Uncontrolled concomitant infection or any unstable medical condition that could interfere with study objectives.
    • Significant liver disease, defined as having, during the past 28 days, consistently elevated Aspartate Aminotransferase, GOT (AST) Serum Glutamic Oxaloacetic Transaminase (SGOT) and/or Alanine Aminotransferase, GPT (ALT) Serum Glutamic Pyruvic Transaminase (SPGT) levels greater than 3 times the upper value of the normal range of the investigational site.
    • Patient currently taking or maintained on another form of extended-release tacrolimus following his/her transplant procedure.
    • Patient who will be maintained on a non-tacrolimus-based maintenance immunosuppressive regimen following his/her transplant procedure.
    • Patient currently taking, having taken within 30 days, or who will be maintained on an Mammalian target of rapamycin (mTOR) inhibitor following his/her transplant procedure.
    • Use of an investigational study drug in the 30 days prior to the transplant procedure.
    • Contraindication or hypersensitivity to drugs or any of their components that constitute the immunosuppression regimen.
    • 6 Antigen (Ag) match or zero mismatch at major Major Histocompatibility Complex (MHC) (class I or class II).
    • Receipt of an Blood Group System (A, B, AB, and O) (ABO)-incompatible organ. Note: A2 donor to O recipient or A2 donor to B recipient is considered ABO-compatible and not excluded by this criterion.
    • Presence of current or historic pre-formed anti-Human Leukocyte Antigen (HLA) DSA against the current donor (evidence of pre-formed, non-donor HLA is not exclusionary) as defined by a subject meeting any of the following criteria*: a) positive virtual crossmatch, b) positive T- or B-cell crossmatch by National Institutes of Health (NIH) antiglobulin lymphocytotoxicity method** , c) .Positive T- or B-cell flow cytometry crossmatch defined by the Multiparameter flow cytometry (MFC) criteria used by the center’s HLA lab for their local proficiency testing.,** d) An Mean Fluorescence Intensity (MFI) greater than or approaching 1000 using flow cytometry/Luminex-based, specific anti-HLA antibody testing.
      • * Patients are eligible to enroll with a negative virtual crossmatch if used in lieu of a physical crossmatch, if, use of such is required to obviate the accrual of excessive ischemia time. However, continued participation is predicated on the performance of the physical crossmatch within 48 hours of transplant. If the physical crossmatch is positive, the subject will be discontinued.
      • ** If b or c above are positive secondary to a suspected positive auto-crossmatch, that is not exclusionary as long as a and b above are not met.
    • Receipt of desensitization, antibody-removal, anti-B-cell, or anti-plasma cell therapy in the 90 days preceding the transplant procedure.
    • Planned initiation (prior to transplant) of desensitization, antibody-removal, anti-B-cell, or anti-plasma cell therapy within 7 days of the transplant procedure.
    • Donor or recipient with known hepatitis C infection (Hepatitis C Virus (HCV) antibody positive), Human Immunodeficiency Virus (HIV) infection (HIV antibody positive), acute hepatitis B infection (Hepatitis B Surface Antigen (HBsAg) positive, anti-Hepatitis B Virus Core (HBc) positive, Immunoglobulin M (IgM) anti-HBc positive, anti-HBs negative) chronic hepatitis B infection (HBsAg positive, anti-HBc positive, IgM anti-HBc negative, anti-HBs negative), or equivocal hepatitis B status (HBsAg negative, anti-HBc positive, anti-HBs negative). Patients (donor or recipient) who have normal liver function tests (LFT) and who are either hepatitis C positive with a negative viral load or have natural or vaccine-acquired immunity from hepatitis B are not excluded by this criterion.
    • Primary focal segmental glomerulosclerosis.
    • Subject has a current malignancy or history of malignancy (within the past 5 years), except non-metastatic basal or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix that has been successfully treated.
    • Recipient of multi-organ or dual kidney transplants (inclusive of current transplant and any prior non-renal transplants). Note: Patients with prior kidney transplants are eligible.
    • Recipient of an en bloc, pediatric deceased donor kidney from a donor less than 5 years of age OR weighing less than 20 kg.
    • Prior graft loss secondary to Cytomegalovirus (CMV) or BK nephropathy.
    • Prior history of invasive organ disease in the presence of CMV or BKV or clinically significant CMV viremia.
    • History of clinically significant BK viruria.
    • Any condition which makes the subject unsuitable for study participation.
    • Planned complete steroid avoidance (Steroid initiation and subsequent taper / withdrawal will be allowed and will be under the purview of the treating physician).
    • Planned receipt of post-transplant prophylactic HCV treatment.

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    Find a Trial
    2

    Why are Clinical Trials Important?

    Learn More
    3

    Why Participate in a Clinical Trial?

    Discover More